Future exploration of mechanisms underpinning a putative effect of TYK2 inhibition in lung carcinogenesis could include genetic epidemiological assessment of the role of immune cell‐mediated cytokine signalling pathways previously shown to be impaired in TYK2‐immunodeficient patients in lung cancer risk (eg, type I interferon, IL10, IL12 and IL23 signalling).8 Here, TYK2 is linked to lung carcinoma.